Setback for Kyowa’s Nouryant in European Parkinson’s disease market – register for free webinar
Join GlobalData on 3 August at 4pm BST for a free webinar on the evolving Parkinson's disease market.
Five AI-enhanced clinical trial start-ups to watch in 2021
We look at some of the most exciting startups harnessing artificial intelligence to improve clinical...
Healthy patients, healthy planet: tackling the carbon footprint of clinical trials
The Sustainable Healthcare Coalition is developing a tool to track carbon emissions from clinical trials.
Nothing to sneeze at: nasal sprays to tackle Covid-19
Pharmaceutical Technology takes a look at some of the nasal sprays in development for the treatment and prevention of Covid-19.
Covid-19 mRNA vaccine booster outlook positive despite heart inflammation risk
Pfizer drew headlines this month when it raised the idea of an emergency authorization for its COVID-19 mRNA vaccine booster to combat the Delta variant. But what does this mean for its rare heart inflammation side effects?
Latest Deals
-
ParexelMergers & Acquisitions $8.5BN
-
ICONMergers & Acquisitions $12BN
-
BEKHealthCapital Raising $4M
-
Hawthorne EffectCapital Raising $20M
-
ParexelMergers & Acquisitions $8.5BN
-
ICONMergers & Acquisitions $12BN
-
BEKHealthCapital Raising $4M
-
Hawthorne EffectCapital Raising $20M
Weekly chart
Top pharma organisations by patents granted in Q2 2021
Pharma groups ranked by patents granted in Q2 2021
| Assignee | Patents |
|---|---|
| F. Hoffmann-La Roche Ltd | 341 |
| Johnson & Johnson | 305 |
| Zhejiang University | 270 |
| Chinese Academy of Sciences | 224 |
| Bristol-Myers Squibb Co | 181 |
| Novartis AG | 178 |
| E. Merck KG | 170 |
| Sanofi | 146 |
| Pfizer Inc | 143 |
| Bayer AG | 105 |
Latest News
I-Mab to commence Phase I Alzheimer’s drug trial in US
In preclinical studies, Protollin showed potency to modify immune cells and treat immune-related ailments.
Yale University study finds low trial data transparency
Large pharmaceutical companies were observed to be more transparent about their trial data than smaller companies.
AstraZeneca Covid-19 shot plus Sputnik Light shows safety in study
Data found no serious adverse events or Covid-19 cases following inoculation with the combination.
NIH advances ACTIV-5/BET-B trial of Humanigen’s lenzilumab for Covid-19
The trial’s primary goal is changed to survival without ventilation based on data from the Phase III LIVE-AIR trial.
Latest Themes
China’s tech future depends on children and surveillance
A bountiful tech industry means the children of China face a prosperous future. The same tech is watching them, and ever evolving, as Giacomo Lee discovers.
The NHS says data saves lives. Smart hospitals may prove it
Matt Hancock's legacy for healthcare in England may be the smart hospital, as Giacomo Lee discovers.
Was Covid-19 the jab needed to make companies fight fake news?
F-Secure, Adobe and O'Reilly speak to Giacomo Lee on how fake news regulation will need more than AI and intelligence from social media heads.
Is the pharma sector seeing the beginnings of a robotics investment boom?
Robotics deals, jobs and patents have been booming in the last few years. But is the pharma sector keeping up?
Lack of trials in pregnant people driving Covid-19 vaccine hesitancy
Studies testing the safety of Covid jabs in pregnant people have only just begun, leaving some hesitant to undergo vaccination.
India may deploy Covid-19 vaccine boosters: Brazil, South Africa unlikely to follow soon
There’s increasing talk of vaccine boosters to combat the Delta variant. But what does this mean in COVID-19 hotspots such as Brazil, South Africa, and India, where the different variants of concern first appeared?
Where are clinical trial operations companies focusing their big data hiring efforts?
Companies are increasingly hiring for big data roles in the pharmaceuticals sector, but some parts of the world are proving more attractive than others.
UK to study long Covid in £20m research drive
Backed by nearly £20 m through the NIHR, 15 new UK studies will expand research into long Covid.
Expert Commentary & Analysis
View MoreAdagrasib has experts cautious if its durability of response in colorectal cancer can be extended
Adagrasib targets an important oncogenic pathway so the tumour will find a workaround, even if...
Best choice between chemo or Braftovi/Erbitux in second-line rare colorectal cancer still debatable
One year since frontline Keytruda made a splash in a rare colorectal cancer subgroup, treatment...
Resumed trials decrease due to rise in Delta variant cases
The number of clinical trials resuming has declined for the first time since the beginning...
Slow recruitment due to Covid-19 disruptions continues to climb
There has been an increase in trials impacted by slow recruitment due to the Covid-19...